Age years | | | | |
18–59 | 7420 (28) | 4.6 | <0.001 | 1 |
60–69 | 10 555 (40) | 6.0 | 1.3 (1.2–1.5) |
70–79 | 7163 (27) | 7.5 | 1.7 (1.5–2.0) |
≥80 | 1139 (4) | 9.8 | 2.3 (1.8–2.9) |
Year of diagnosis | | | | |
2010 | 4253 (16) | 6.4 | 0.15 | |
2011 | 4254 (16) | 7.0 |
2012 | 4389 (17) | 6.2 |
2013 | 4364 (17) | 6.1 |
2014 | 4475 (17) | 5.6 |
2015 | 4542 (17) | 6.0 |
Sex | | | | |
Male | 14 719 (56) | 6.5 | 0.03 | |
Female | 11 558 (44) | 5.8 |
Stage | | | | |
IIIA | 4515 (17) | 2.5 | <0.001 | ¶ |
IIIB | 4330 (16) | 3.6 |
IV | 17 432 (66) | 7.8 |
Histology | | | | |
Adenocarcinoma | 10 883 (41) | 5.3 | <0.001 | 1 |
Squamous | 4414 (17) | 4.4 | 1.1 (0.9–1.3) |
Other NSCLC | 3770 (14) | 6.5 | 1.4 (1.2–1.6) |
SCLC | 7210 (27) | 8.5 | 1.7 (1.5–1.9) |
Metastatic sites involved n | | | | |
0 | 8841 (34) | 3.0 | <0.001 | 1 |
1 | 9182 (35) | 6.0 | 2.1 (1.8–2.4) |
2 | 4865 (19) | 8.6 | 3.0 (2.6–3.5) |
≥3 | 3389 (13) | 11.5 | 4.3 (3.7–5.1) |
Type of treatment | | | | |
Chemotherapy | 25 010 (95) | 6.1 | <0.001 | 1 |
Targeted | 1267 (5) | 8.6 | 1.3 (1.1–1.6) |